At a glance
ClinicalIndex Comparison RecordN/ACompleted· 12 target
Drug / intervention
pramlintide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effect of Pramlintide on Meal Time Insulin Bolus
In Brief
A clinical study evaluating pramlintide and continuous glucose monitoring for Type 1 Diabetes. Completed, enrolled 12 participants.
Detailed Summary
The primary objective is to establish the mean percentage of change in the insulin-to-carbohydrate ratio due to pramlintide treatment once a maximum tolerated dose or 6 mcg before each meal is reached. The secondary objective is to establish which insulin bolus wave form is associated with the lowest post-bolus without hypoglycemia in subjects treated with maximum pramlintide dosage.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 1 Diabetes
Countries--
CollaboratorsAmylin Pharmaceuticals, LLC.
Timeline
N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 2007
Enrollment StartSep 2007
Primary CompletionNov 2008
TodayJul 2026
First PostedApr 13, 2007
Enrollment StartSep 1, 2007
Primary CompletionNov 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 19.2 years ago
Interventions
pramlintidedrug
continuous glucose monitoringprocedure